CHRS
NASDAQ
US
Coherus Oncology, Inc. - Common Stock
$1.73
▼ $-0.01
(-0.57%)
Vol 537K
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$171.6M
P/E
1.1
ROE
252.6%
Margin
185.4%
D/E
57.63
Beta
0.97
52W
$1–$2
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.35 | $-0.34 | +$0.01 |
| Sep 2025 | $-0.33 | $-0.33 | +$0.00 |
| Jun 2025 | $-0.30 | $-0.34 | $-0.04 |
| Mar 2025 | $-0.24 | $-0.35 | $-0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $54.1M | $7.6M | $10.3M | $11.6M | $12.7M |
| Net Income | — | -$50.7M | -$56.6M | $297.8M | -$35.5M | -$37.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 248.5% | 248.5% | 248.5% | 248.5% | 252.6% | 252.6% |
| P/E (TTM) | 0.47 | 0.69 | 1.06 | 1.09 | 0.90 | 1.11 |
| Net Margin | 2903.9% | 125.9% | 125.9% | 125.9% | 185.4% | 185.4% |
| Gross Margin | 66.9% | 57.5% | 57.5% | 57.5% | 47.8% | 47.8% |
| D/E Ratio | 41.70 | 41.70 | 41.70 | 41.70 | 57.63 | 57.63 |
| Current Ratio | 1.44 | 1.44 | 1.44 | 1.44 | 1.24 | 1.24 |
Key Ratios
ROA (TTM)
34.9%
P/S (TTM)
2.05
P/B
12.5
EPS (TTM)
$1.33
CF/Share
$-2.49
Rev Growth 3Y
-6.5%
52W High
$1.89
52W Low
$0.71
$0.71
52-Week Range
$1.89
Financial Health
Free Cash Flow
-$19.7M
Net Debt
-$48.5M
Cash
$88.9M
Total Debt
$40.3M
As of Dec 31, 2025
How does CHRS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CHRS valuation vs Biotechnology peers
P/E ratio
1.1
▼
94%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.1
▼
84%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
12.5
▲
410%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CHRS profitability vs Biotechnology peers
ROE
252.6%
▲
475%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
185.4%
▲
165%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
47.8%
▼
39%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
34.9%
▲
175%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CHRS financial health vs Biotechnology peers
D/E ratio
57.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.2
▼
72%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.0
▼
0%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
CHRS fundamentals radar
CHRS
Peer median
Industry
CHRS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CHRS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
LANFEAR DENNIS M
Chief Executive Officer · Jan 23
375000 shs
MCMICHAEL BRYAN J
Chief Financial Officer · Jan 22
112500 shs
Last 90 days
Top Holders
Top 5: 19.42%Blackrock Inc.
7.05%
$17.2M
Vanguard Group Inc
6.69%
$16.3M
Kohlberg Kravis Roberts & C…
2.03%
$4.9M
Geode Capital Management, L…
1.83%
$4.5M
Tang Capital Management, LLC
1.82%
$4.4M
As of Dec 31, 2025
Latest News
No related news yet